FDA DEVICE FACTS
TRIWAY Tibiotalocalcaneal (TTC) Arthrodesis System
In2bones Sas
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Complete original indications for use
The TRIWAY® TTC Arthrodesis System is intended for use in tibiotalocalcaneal arthrodesis and treatment of trauma to the hindfoot and distal tibia. Examples include: Post-traumatic and degenerative arthritis involving both ankle and subtalar joints Rheumatoid arthritis with severe deformity Revision of failed ankle arthrodesis with subtalar involvement or with insufficient talar body Revision of failed total ankle arthroplasty with subtalar intrusion Talar deficiency conditions, including avascular necrosis (requiring a tibiocalcaneal arthrodesis) Neuroarthropathy or neuromuscular deformity or other neuromuscular disease with severe deformity or instability of the ankle, including Charcot foot Severe pilon fractures with trauma to the subtalar joint Malunited tibial pilon fractures The addition of an IBS™ 6.5mm compression screw through the subtalar joint and through the nail is required.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。